The antiandrogen withdrawal syndrome
- VernacularTitle:抗雄激素撤除综合征
- Author:
Lixin HUA
;
Hongfei WU
;
Yuangeng SUI
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Carcinoma;
Prostate specific antigen;
Antiandrogen withdrawal
- From:
Chinese Journal of Urology
1994;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the occurrence of antiandrogen withdrawal syndrome in patients with advanced prostate cancer treated with combined androgen blockade. Methods 24 cases of advanced prostate cancer (10 in stage C and 14 in stage D) were retrospectively studied. All the patients have been treated with combined androgen blockade (bilateral orchiectomy and flutamide). After initial beneficial response to hormonal therapy (duration 7 to 36 months), the disease became progressing.Flutamide was then discontinued. Serum prostate specific antigen (PSA) levels and symptoms alterations were observed. Results Following withdrawal of flutamide, 8 patients showed a decline in PSA (mean 75%).In 6 the PSA declined more than 50%. Clinical symptoms improved in 4 patients and the prostate mass became smaller in 2. The mean duration of improvement was 4.3 months. Conclusions In patients with hormone refractory prostate cancer after initial combined androgen blockade, a trial of "antiandrogen withdrawal" is a reasonable therapeutic management prior to other more toxic therapies.
